Selected Grants
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)
ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2017 - 2028Diabetic Retinopathy Clinical Research Network (DRCR.net)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2010 - 2028A Ph 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
ResearchPrincipal Investigator · Awarded by Annexon Biosciences · 2024 - 2027A Phase 2 Randomized, Controlled, Double-Masked Trial to Evaluate the Safety and Efficacy of Intravitreal 4D-150 Gene Therapy in Adults with Diabetic Macular Edema (SPECTRA Study)
ResearchPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2023 - 2027A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)
ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2017 - 2028Diabetic Retinopathy Clinical Research Network (DRCR.net)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2010 - 2028A Ph 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
ResearchPrincipal Investigator · Awarded by Annexon Biosciences · 2024 - 2027A Phase 2 Randomized, Controlled, Double-Masked Trial to Evaluate the Safety and Efficacy of Intravitreal 4D-150 Gene Therapy in Adults with Diabetic Macular Edema (SPECTRA Study)
ResearchPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2023 - 2027A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis (CLARITY)
ResearchPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2024 - 2027A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PIVOTAL PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA_EYE-RES-102
ResearchPrincipal Investigator · Awarded by Eyebiotech Ltd. · 2024 - 2027A Clinical Trial to Evaluate Intravitreal 4D-175 Gene Therapy in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration; 4D-175-C001 (GAZE)
ResearchPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2024 - 2027Ocular Therapeutix DRC Ph 3 study in subjects with nAMD_OTX-TKI-2023
ResearchPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2023 - 2027NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027Genentech DRC A MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY WITH OR WITHOUT DME
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2027Genentech-A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A GENENTECH SPONSORED STUDY
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2026Learning-based 3D modeling of AMD to assess disease progression and response to treatment
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2026A PHASE 1 OPEN-LABEL CLINICAL TRIAL TO ESTABLISH THE SAFETY, TOLERABILITY, DOSE RANGE, AND PHARMACOKINETIC PROFILE OF INTRAVITREAL INJECTION OF TH103 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (THEIA1000)
ResearchPrincipal Investigator · Awarded by Kalaris Therapeutics, Inc. · 2024 - 2026Novartis DRC An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2018 - 2026A Phase 1/2 Dose-Escalation and Dose-Randomized, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration
ResearchPrincipal Investigator · Awarded by 4D Molecular Therapeutics · 2021 - 2025A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2
ResearchPrincipal Investigator · Awarded by Neurotech Pharmaceuticals, Inc. · 2024 - 2025Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F (RUSH1F)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2021 - 2025Rate of Progression in EYS-Related Retinal Degeneration (PRO-EYS)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2019 - 2025Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2025Safety, tolerability, and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 in patients with geographic atrophy secondary to age-related macular degeneration (open label, non-randomized).
ResearchPrincipal Investigator · Awarded by Ora, Inc. · 2023 - 2025Novartis DRC Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2025A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULA
ResearchPrincipal Investigator · Awarded by Roche TCRC, Inc · 2021 - 2025Lumithera DRC A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects with Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
ResearchPrincipal Investigator · Awarded by LumiThera, Inc. · 2019 - 2025"A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema (Aspire)" UBX1325-04
ResearchPrincipal Investigator · Awarded by UNITY Biotechnology · 2023 - 2024A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2024A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2024A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (LUCERNE)
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2024A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2024Novartis DRC A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2024A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 IN COMBINATION WITH RANIBIZUMB ADMINISTERED INTRAVITREALLY I
ResearchPrincipal Investigator · Awarded by Roche TCRC, Inc · 2021 - 2024Evaluation of KPI-012's protective effects on RPE cells
ResearchPrincipal Investigator · Awarded by Combangio, Inc. · 2022 - 2024A 2-part study of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal EYE103 (Restoret®) in a mixed population of participants with DME and NVAMD
ResearchPrincipal Investigator · Awarded by Eyebiotech Ltd. · 2023 - 2024ROCHE DRC PH 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RO7250284 FOLLOWING ITV ADMINISTRATION OF UNMASKED MULTIPLE ASCENDING DOSES AND MASKED SUSTAINED DELIVERY FROM THE PORT DELIVERY SYSTEM IN PATIENTS WITH NAMD
ResearchPrincipal Investigator · Awarded by Hoffman-La Roche, Inc. · 2020 - 2024FFB DRC Gyrate Atrophy Ocular and Systemic Study (GYROS)
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2022 - 2024Ripple DRC Ph 2 Evaluation of Safety and Efficacy of IBE-814 IVT Implant - A Sustained, Low Dose Dexamethasone Therapy for the Treatment of Patients with Diabetic Macular Edema (DMO) and Macular Edema due to Retinal Vein Occlusion (RVO).
ResearchPrincipal Investigator · Awarded by Ripple Therapeutics · 2020 - 2024FFB Universal Rare Gene study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants
ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2022 - 2024A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
ResearchPrincipal Investigator · Awarded by Annexon Biosciences · 2020 - 2024A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE
ResearchPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2022 - 2024Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2024GENENTECH DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2024A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Safety and Tolerability of Oral PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis
ResearchPrincipal Investigator · Awarded by Pipeline Therapeutics, Inc · 2022 - 2024IONIS DRC A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to AMD
ResearchPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2019 - 2023A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with nAMD
ResearchPrincipal Investigator · Awarded by UNITY Biotechnology · 2021 - 2023IVERIC DRC PH 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA¿ (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
ResearchPrincipal Investigator · Awarded by IVERIC bio, Inc. · 2020 - 2023Novartis DRC A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular degeneration (SWIFT)
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2023Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
ResearchPrincipal Investigator · Awarded by Ocuphire Pharma, Inc. · 2021 - 2023LMRI DRC Phase 3 Clinical Trial of CNTF for MacTel Type 2-NTMT-03
ResearchPrincipal Investigator · Awarded by The Lowy Medical Research Institute · 2017 - 2023A Ph3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety/Efficacy Study of a Fluocinolone Acetonide Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
ResearchPrincipal Investigator · Awarded by Eyepoint Pharmaceuticals · 2021 - 2023A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.
ResearchPrincipal Investigator · Awarded by Hexal AG · 2020 - 2023A Phase 1b, Prospective, Multicenter, Randomized, Single Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema (DME)
ResearchPrincipal Investigator · Awarded by UNITY Biotechnology · 2020 - 2023Roche DRC Multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability,pharmacokinetics, and pharmacodynamics of RO7200394 following intravitreal administration in patients with nAMD
ResearchPrincipal Investigator · Awarded by Hoffman-La Roche, Inc. · 2019 - 2023Evaluation of the Heidelberg Engineering SPECTRALIS with Flex Module for In-vivo Imaging in the Supine Position
ResearchPrincipal Investigator · Awarded by Heidelberg Engineering · 2020 - 2022ONL DRC A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off, Rhegmatogenous Retinal Detachment
ResearchPrincipal Investigator · Awarded by ONL Therapeutics · 2019 - 2022SCD DRC A Phase 3 Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration
ResearchPrincipal Investigator · Awarded by Sam Chun Dang Pharm. Co., Ltd · 2019 - 2022Gemini DRC NH01 Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-central GA Who Are Carriers of High-risk Genetic Complement Variants Associated with Dry AMD
ResearchPrincipal Investigator · Awarded by Gemini Therapeutics · 2018 - 2022Gemini DRC A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-central Geographic Atrophy (GA) Who Are Carriers of High-risk Genetic Variants of Complement Factor H (CFH)
ResearchPrincipal Investigator · Awarded by Gemini Therapeutics · 2018 - 2022Regeneron DRC A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
ResearchPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2019 - 2022Gemini DRC A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
ResearchPrincipal Investigator · Awarded by Gemini Therapeutics · 2020 - 2022Genentech -A PHASE III RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE COMPARATOR, MULTICENTER EVALUATION OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH nAMD
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2022Brolucizumab Switch and Extend Ph IIIb Study: A Canadian, multi-center, single-arm, open label study assessing the efficacy and safety of brolucizumab 6mg in a Treat and Extend regimen in patients with nAMD with prior anti-VEGF exposure (PEREGRINE)
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2022Novartis DRC A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg dosed Q4 weeks compared to Q8 weeks in high anti-VEGF-need patients with neovascular age-related macular degeneration (nAMD)
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2022A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.
ResearchPrincipal Investigator · Awarded by Eyevensys · 2017 - 2022Regenxbio DRC A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)
ResearchPrincipal Investigator · Awarded by Regenxbio, Inc. · 2018 - 2022GEMINI DRC Ph1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients with Geographic Atrophy (GA) Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103
ResearchPrincipal Investigator · Awarded by Gemini Therapeutics · 2019 - 2022Novartis DRC HAWK Centralized Imaging and Adjudication services, RTH258A/C1001502/I150 RTH258A2301
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2021Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy
ResearchPrincipal Investigator · Awarded by Kato Pharmaceuticals, Inc · 2019 - 2021A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 (pEYS606 administered by injection and electrotransfer to the ciliary muscle) Treatment Regimens in Patients with CNIU
ResearchPrincipal Investigator · Awarded by Eyevensys · 2019 - 2021LMRI DRC MacTel Phase II
Clinical TrialPrincipal Investigator · Awarded by The Lowy Medical Research Institute · 2013 - 2021Santen DRC AVANTE Study (Phase II) - Assess Efficacy, Safety of Intravitreal Injections of DE-122 in combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Wet AMD
ResearchPrincipal Investigator · Awarded by Santen, Ltd. · 2017 - 2021Hemera DRC A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration with Geographic Atrophy
ResearchPrincipal Investigator · Awarded by Hemera Biosciences · 2020 - 2021QLT DRC RET IRD 04: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)
ResearchPrincipal Investigator · Awarded by QLT, Inc. · 2016 - 2021A PHASE 2/3 RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTIONS TO SUBJECTS WITH ACUTE NON ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION)
ResearchPrincipal Investigator · Awarded by Quark Pharmaceuticals, Inc · 2015 - 2021Senju DRC A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients with Age-Related Macular Degeneration
ResearchPrincipal Investigator · Awarded by Senju Pharmaceutical Co, Ltd. · 2019 - 2021Astellas DRC Phase 1b, Dose Escalation Evaluation of Safety and Tolerability and a Ph 2, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to AMD
ResearchPrincipal Investigator · Awarded by Astellas Institute for Regenerative Medicine · 2017 - 2021A PHASE IIIb OPEN-LABEL, SINGLE-ARM STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE USABILITY OF RANIBIZUMAB 10 mg/0.1 mL PREFILLED SYRINGE WITH THE PORT DELIVERY SYSTEM
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2021Thrombogenics DRC A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME)
ResearchPrincipal Investigator · Awarded by ThromboGenics Inc · 2018 - 2021Thrombogenics DRC - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)
ResearchPrincipal Investigator · Awarded by ThromboGenics Inc · 2018 - 2021UPENN - Additional Analysis of Data from the Comparison of Age-related Macular Degeneration Treatments Trials CATT and CATT Follow-up Study (CATT FS)
ResearchPrincipal Investigator · Awarded by University of Pennsylvania · 2019 - 2021Mallinckrodt DRC A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate, Posterior, or Panuveitis
ResearchPrincipal Investigator · Awarded by Mallinckrodt Pharmaceuticals · 2019 - 2020Allgenesis DRC A Multicenter, Prospective, Randomized, Double-masked Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium
ResearchPrincipal Investigator · Awarded by Allgenesis Biotherapeutics · 2018 - 2020Evaluation of retinal cavitations in macular telangiectasia type 2 and response to ciliary neutrophic factor (CNTF)
FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2018 - 2020DRC Editas Natural History Study of CEP290-Related Retinal Degeneration
ResearchPrincipal Investigator · Awarded by Editas Medicine Inc. · 2018 - 2020An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Flucinolone Acetonide Intravitreal Implant
Clinical TrialPrincipal Investigator · Awarded by Bausch & Lomb Incorporated · 2016 - 2020AN OBSERVATIONAL BILATERAL EVALUATION OF CORNEAL ENDOTHELIAL CELL DENSITY IN SUBJECTS WHO HAVE HAD A FLUOCINOLONE ACETONIDE IMPLANT FOR AT LEAST ONE YEAR
Clinical TrialPrincipal Investigator · Awarded by Bausch & Lomb Incorporated · 2016 - 2020A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY
ResearchPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2017 - 2020Macular Edema Treatment Trials Associated with MUST (META-MUST)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2016 - 2020A Multi-Center, Open-Label, Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 (travoprost) Intracameral Implant in Subjects with Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
ResearchPrincipal Investigator · Awarded by Envisia Therapeutics · 2015 - 2020A CONTROLLED, MULTI-CENTER STUDY OF THE UTILIZATION AND SAFETY OF THE MK II INSERTER AND THE SAFETY OF THE FAI INSERT IN SUBJECTS WITH NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
Clinical TrialPrincipal Investigator · Awarded by pSivida Corporation · 2016 - 2020A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, CROSSOVER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EXPLORATORY EFFICACY OF 1.0 mg LUMINATE® (ALG-1001) AS A TREATMENT FOR NON-EXUDATIVE MACULAR DEGENERATION
ResearchPrincipal Investigator · Awarded by Allegro Ophthalmics, LLC · 2017 - 2019Ophthotech DRC Phase 2 OPH2007 - A Phase 2A Open-Label Trial to ASSESS the Safety of Zimura¿ (anti-c5) Administered in Combination With Lucentis® 0.5 mg in Treatment naive subjecTs with Neovascular Age related macular degeneration
ResearchPrincipal Investigator · Awarded by Ophthotech Corp. · 2018 - 2019pSivida PSV-FAI-001 Duke as Site
Clinical TrialPrincipal Investigator · Awarded by pSivida Corporation · 2013 - 2019SciFluor DRC Wet AMD study
ResearchPrincipal Investigator · Awarded by SciFluor Life Sciences · 2018 - 2019A prospective, single-center, randomized, double masked, sham controlled study to evaluate the safety, efficacy and tolerability of OTX-TI (sustained release travoprost) Intracameral Depot compared to topical travoprost in subjects with OA & OHT.
ResearchPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2017 - 2019PRN/Stealth DRC An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects with Intermediate Age-Related Macular Degeneration
ResearchPrincipal Investigator · Awarded by PRN Pharmaceutical Research Network, LLC · 2016 - 2018Computer Aided Classification of Diabetic Macular Edema
ResearchCollaborator · Awarded by National Institutes of Health · 2012 - 2018A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
ResearchPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2016 - 2018A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema
ResearchPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2016 - 2018Acucela DRC A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease
ResearchPrincipal Investigator · Awarded by Acucela Inc. · 2016 - 2018A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies
ResearchPrincipal Investigator · Awarded by Cleave Biosciences · 2016 - 2018ThromboGenics DRC OASIS study - provide raw images
ResearchPrincipal Investigator · Awarded by ThromboGenics Inc · 2017 - 2018A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2015 - 2017UPenn - NEI Follow-up Study: Comparison of AMD Treatment Trials (CATT) YR3
ResearchPrincipal Investigator · Awarded by University of Pennsylvania · 2013 - 2017Neurotech DRC NT-503 (GEN 3)
Clinical TrialPrincipal Investigator · Awarded by Neurotech USA, Inc. · 2014 - 2017Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to AMD
ResearchPrincipal Investigator · Awarded by Ocata Therapeutics, Inc. · 2015 - 2017Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2009 - 2017A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects with Behcet's Disease Uveitis
ResearchPrincipal Investigator · Awarded by XOMA (US) LLC · 2014 - 2017River Vision DRC DME
ResearchPrincipal Investigator · Awarded by River Vision Development Corporation · 2014 - 2017Alcon DRC OVID II RTH255-P001
ResearchPrincipal Investigator · Awarded by Alcon Research, Inc. · 2015 - 2017A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2016 - 2016A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg) monotherapy, in patients with nAMD
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2016 - 2016Coordinating Center for the Comparison of AMD Treatments Trials
ResearchCo Investigator · Awarded by University of Pennsylvania · 2014 - 2015Comparison of AMD Treatment Trials-OCT Reading Center
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2013CATT OCT Reading Center
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2011Cytokine Modulation in Proliferative Vitreoretinopathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 2006Cytokine Modulation In Proleferative Vitreoretinopathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 1999Cytokine Modulation In Proliferative Vitreoretinopathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 1996Cytokine Modulation In Proliferative Vtreoretinopathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1996Modulation Of Na+K+ Atpase In Retinal Detachment
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1989 - 1990External Relationships
- 4D Molecular Therapeutics
- Annexon Biosciences, Inc.
- BlueRock Therapeutics
- EyePoint
- Genentech Roche
- 4D Molecular Therapeutics
- Annexon Biosciences, Inc.
- BlueRock Therapeutics
- EyePoint
- Genentech Roche
- Kriya Therapeutiucs
- Neurotech
- Ocular Therapeutix Inc.
- Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.